NCT06966843View on ClinicalTrials.gov

Dantrolene in Statin-induced Myopathy

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 31, 2027

Primary Completion Date

January 31, 2029

Study Completion Date

March 31, 2030

Conditions
Statins Induced Myopathy
Interventions
DRUG

Dantrolene

Dantrolene sodium capsule 25 mg orally once daily for 4 weeks. Dose may be titrated to 50 mg daily after 1 week if tolerated. Used to assess impact on muscle pain and biomarkers of muscle injury in patients with statin-induced myopathy.

DRUG

Placebo

Oral placebo capsule matching dantrolene in size and appearance, administered once daily for 4 weeks.

All Listed Sponsors
lead

Tanta University

OTHER